

**EARLY WARNING REPORT
PURSUANT TO NATIONAL INSTRUMENT 62-103**

Section 102 of the *Securities Act* (Ontario)

1. Name and address of the offeror:

Invidx Corp. (the “Offeror”)
6 Trout Lily Ave
Markham, ON L3S 4C1

2. Name of reporting issuer with respect to which this report is filed:

ChroMedX Corp. (the “Company”)

3. Designation and number or principal amount of securities and the offeror’s securityholding percentage in the class of securities of which the offeror acquired ownership or control in the transaction or occurrence giving rise to the obligation to file the report, and whether it was ownership or control that was acquired in those circumstance:

On December 15, 2014, the Offeror acquired 5,474,452 common shares in the capital of the Company (“**Common Shares**”) from the Company, representing approximately 14.73% of the outstanding Common Shares of the Company in connection with the Company’s exercise of an ultrafiltration option (the “**Exercise**”).

4. Designation and number or principal amount of securities and the offeror’s securityholding percentage in the class of securities immediately after the transaction or occurrence giving rise to obligation to file the report:

Following the Exercise indicated in paragraph 3, the Offeror, directly holds an aggregate of 20,474,552 Common Shares, representing approximately 47.75% of the outstanding Common Shares (based on 42,874,644 issued and outstanding Common Shares as at the date hereof). The Offeror does not own any convertible securities of the Company.

5. Designation and number or principal amount of securities and the percentage of outstanding securities of the class of securities referred to in paragraph 4 over which:

- (i) **the offeror, either alone or together with any joint actors, has ownership and control;**

The Offeror directly owns the securities referred to in paragraph 4.

- (ii) **the offeror, either alone or together with any joint actors, has ownership but control is held by other persons or companies other than the offeror or any joint actor; and**

Not applicable.

- (iii) the offeror, either alone or together with any joint actors, has exclusive or shared control but does not have ownership.**

Not applicable.

- 6. Name of the market in which the transaction or occurrence that gave rise to the report took place:**

Not applicable. The Common Shares were issued to the Offeror by the Company from its treasury in connection with the Exercise – see Paragraph 9.

- 7. The value, in Canadian dollars, of any consideration offered per security if the offeror acquired ownership of a security in the transaction or occurrence giving rise to the obligation to file a report.**

The Company issued to the Offeror 5,474,452 Common Shares at a deemed price of \$0.274 per share. The Offeror, in consideration for issuance of the 5,474,452 Common Shares received from the Company in connection with the Exercise – see Paragraph 9.

- 8. Purpose of the offeror and any joint actors in effecting the transaction or occurrence that gave rise to the report, including any future intention to acquire ownership of, or control over, additional securities of the reporting issuer:**

The Offeror has acquired the above-noted securities of the Company for investment purposes and the Offeror may, depending on market and other conditions, increase or decrease its beneficial ownership, control or direction over the common shares or other securities of the Company, through market transactions, private agreements, treasury issuances, exercise of convertible securities or otherwise. See Paragraph 9.

- 9. General nature and the material terms of any agreement, other than lending arrangements, with respect to securities of the reporting issuer entered into by the offeror, or any joint actor, and the issuer of the securities or any other entity in connection with the transaction or occurrence giving rise to the report, including agreements with respect to the acquisition, holding, disposition or voting of any of the securities:**

The Company exercised the option to acquire patent application PCT/CA2013/050935 related to Automated Ultrafiltration Technology and associated intellectual property (“AUF”) from the Offeror pursuant to an option agreement dated June 16, 2014 (the “**Option Agreement**”), whereby the Offeror agreed to assign the AUF to the Company for a purchase price of CDN\$1,500,000.

As consideration for the acquisition of the AUF the Company issued 5,474,452 Common Shares which was determined based on the 20% discount to the 10-day volume weighted average price of the Company’s Common Shares immediately preceding the date of the option as per the terms of the Option Agreement.

- 10. Names of any joint actors in connection with the disclosure required by this report:**

Not applicable.

- 11. In the case of a transaction or occurrence that did not take place on a stock exchange or other market that represents a published market for the securities, including an issuance from treasury, the nature and value of the consideration paid by the offeror.**

The Common Shares were issued to the Offeror by the Company from its treasury in connection with an Exercise – see Paragraph 9.

- 12. Where applicable, a description of any change in any material fact set out in a previous report filed under the early warning requirements of applicable Canadian securities legislation.**

Not applicable.

- 13. Where applicable, a description of the exemption from securities legislation being relied on by the offeror and the facts supporting the reliance.**

Not applicable.

DATED this 15th day of December, 2014.

INVIDIX CORP.

Per: “Lorna Samsoundar” (signed)

Name: Lorna Samsoundar

Title: President